Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 16/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 16/20 | 0.48 |
| ▸ | ABL1 | P00519 | 9/20 | 0.48 |
| ▸ | KIT | P10721 | 4/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.48 |
| ▸ | BCR | P11274 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943727 | 0.93 | DDR2 (0.53) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL21942989 | 0.90 | DDR2 (0.50) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL21943723 | 0.90 | DDR2 (0.56) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL21943083 | 0.88 | DDR2 (0.49) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL21944042 | 0.88 | KDR (0.54) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL21943388 | 0.87 | CSF1R (0.58) | ABL1KIT | |
| SCHEMBL21943345 | 0.84 | KIT (0.58) | DDR1ABL1KIT | |
| SCHEMBL21942980 | 0.84 | DDR2 (0.52) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL21943733 | 0.84 | DDR2 (0.49) | DDR2DDR1ABL1KITNTRK1 | |
| SCHEMBL21975687 | 0.83 | DDR2 (0.47) | DDR2DDR1ABL1KITNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | XIAMEN UNIVERSITY (CN) | 2022-05-03 | — | — | US | disclosed |
| EP-3647313-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Xiamen University (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP4A11, CYP2D6, CYP3A43 | DDR2 4208/4885DDR1 3948/4885ABL1 78/4885 |
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | CYP4A11, CYP2D6, CYP3A43 | DDR2 4208/4885DDR1 3948/4885ABL1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.